Pricing Log in Create free account

Climb Bio, Inc. (CLYM) vs Solid Biosciences Inc. (SLDB)

Climb Bio, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Climb Bio, Inc. and Solid Biosciences Inc. are of similar size ($626.6M and $615.5M). Across the 9 metrics below, Climb Bio, Inc. leads on 6 and Solid Biosciences Inc. on 3.

Valuation

Metric CLYM SLDB Biotechnology median
P/E n/m n/m 8.50
P/S n/m 70.64 9.71
P/B 3.12 2.12 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 37.04 9.21
Earnings yield (8.45%) (34.54%) (33.15%)
Free cash flow yield (7.11%) (23.62%) (25.50%)

Profitability

Metric CLYM SLDB Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (27.10%) (65.50%) (56.36%)
Return on assets (26.27%) (56.83%) (48.04%)
Return on invested capital (71.73%) 0.00% 0.00%

Growth

Metric CLYM SLDB Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 42.48% 34.97% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLYM SLDB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 31.45 13.82 4.72
Net debt to EBITDA 1.44 1.05 0.96

Dividend

Metric CLYM SLDB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLYM SLDB Biotechnology median
Market cap 626.63m 615.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack